Sign in Subscribe

Biomedical Innovation

New therapies, medical breakthroughs, emerging technologies

Abivax: Ahead of a bright future?

Abivax: Ahead of a bright future?

SPECIAL REPORT 25.07 Abivax: Ahead of a bright future? On Tuesday, July 22, just after the closure of Wall Street, Abivax announced positive phase 3 results for the treatment of ulcerative colitis (UC). The Paris and Boston-based biotechnology company conducted two clinical studies (ABTECT-1 and ABTECT-2 in 8 week

Targeted protein degradation

Targeted protein degradation

SPECIAL REPORT 25.5 Scientific publication This article was published in a different format in the April issue of MedNous Learn more The development of new drugs is dependent on many factors, and one of the most important is being able to identify and reach a target. For years, a

The European Commission approves Leqembi®

The European Commission approves Leqembi®

Scientific publication This article was published in a different format in the April issue of MedNous The Alzheimer’s disease drug, Leqembi® (lecanemab), has been approved by the European Commission following extra reviews of the product’s safety. The decision was announced on 16 April by the product’s co-developer

Alzheimer’s disease : Beyond the beta amyloid hypothesis

Alzheimer’s disease : Beyond the beta amyloid hypothesis

SPECIAL REPORT 25.4 Scientific publication This article which was published in a different format in the February 2025 issue of MedNous presents work underway on candidate diagnostics, new concepts and late-stage therapies, to deliver a new generation of Alzheimer’s treatments. Learn more Summary Alzheimer’s disease is a

Une approche diagnostique holistique de la maladie d’Alzheimer.

Une approche diagnostique holistique de la maladie d’Alzheimer.

SPECIAL REPORT 24.13 La maladie d’Alzheimer reste une pathologie très complexe qui probablement ne se vaincra pas par la découverte d’un vaccin miracle comme on l’espérait en 1999, après la publication dans Nature d’une étude menée par Dale Shenk. Pendant près de trois décennies la

UK approves Kisunla for the treatment of Alzheimer’s disease but NICE …does not pay for it.

UK approves Kisunla for the treatment of Alzheimer’s disease but NICE …does not pay for it.

SPECIAL REPORT 24.12 On October 23, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the licensing of Eli Lilly’s Donanemab or Kisunla for the treatment of early stage Alzheimer’s disease, but the health technology agency National Institute for Health and Care Excellence (NICE) said

Medicinal Chemistry: A great past, an underestimated future

Medicinal Chemistry: A great past, an underestimated future

SPECIAL REPORT 24.09 The following testimonial was delivered by Jean-Claude Muller, former President (1996-1998) of the European Federation for Medicinal chemistry and Chemical biology (EFMC) at the Opening Ceremony of the XXVIII EFMC-International Symposium on Medicinal Chemistry (ISMC) in Rome (Italy) on September 1, 2024. Dear Fellow Chemists Ever